Davita Inc vs Sunrun Inc — how do they compare? Davita Inc trades at $178.01 (market cap $11.29B), while Sunrun Inc trades at $7.63 (market cap $1.83B). The key difference: Davita Inc is far larger — about 6.2× Sunrun Inc's market cap, and Davita Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Sunrun Inc for 16 Days on average.
| DVA | RUN | |
|---|---|---|
Market Cap | $11.29B | $1.83B |
Volume | 582,204 | 8,672,852 |
Sector | Health | Energy |
52-Week High | $240.96 | $21.41 |
52-Week Low | $103.87 | $7.59 |
Typical Hold Time | 113 Days | 16 Days |
Enterprise Value | $24.01B | $16.35B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Sunrun (RUN) trades at $7.61, down 2.06% amid broader solar sector weakness. The stock shows bearish technical signals with resistance at $8, while fundamentals reveal mixed results: strong valuation metrics (P/E 5.16, P/S 0.59) contrast with negative operating cash flow and high debt levels. Recent positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.
Despite attractive valuations and analyst optimism (62% buy rating, $16.56 target), RUN faces significant headwinds from high borrowing costs impacting solar financing, weak underlying business trends, and persistent cash burn. The stock presents a high-risk opportunity with substantial upside potential if execution improves, but requires careful monitoring of cash flow stabilization and subscriber growth metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →